Related Experiment Videos
Gold salts inhibit osteoclastic bone resorption in vitro
Summary
Gold salts used to treat rheumatoid arthritis (RA) inhibit bone resorption by osteoclasts. This study shows gold compounds reduce osteoclast activity and survival, suggesting a mechanism for RA treatment.
Area of Science:
- Biochemistry
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is linked to bone loss driven by increased osteoclast activity.
- The precise mechanism of action for gold salts, a common RA therapy, remains unclear.
Purpose of the Study:
- To investigate the effects of three gold salts (auranofin, aurothioglucose, aurothiomalate) on osteoclast-mediated bone resorption in vitro.
- To determine if gold salts directly impact osteoclast survival and function relevant to RA bone loss.
Main Methods:
- Utilized an in vitro bone slice assay with osteoclasts from neonatal rat long bones.
- Assessed gold salt inhibition of bone resorption and osteoclast survival.
- Conducted cytotoxicity assays on osteoblast-like UMR-106 cells.
Main Results:
- All three gold salts demonstrated dose-dependent inhibition of osteoclastic bone resorption.
- Auranofin (AF) showed an IC50 of 0.1 µg/ml, while aurothioglucose (ATG) and aurothiomalate (ATM) had IC50 values of 1 µg/ml.
- High concentrations of gold salts reduced osteoclast survival, indicating a cytotoxic effect also observed in UMR-106 cells.
Conclusions:
- Gold salts inhibit osteoclastic bone resorption and osteoclast survival at therapeutic concentrations.
- These findings suggest that inhibiting osteoclast activity may be a key mechanism underlying the therapeutic benefits of gold salts in RA.